Newly Diagnosed EGFR+ mNSCLC With CNS Involvement and Treatment Personalization

Panelists discuss how molecular testing and biomarker profiling guide individualized first-line treatment planning for EGFR-mutant non–small cell lung cancer (NSCLC) with central nervous system (CNS) involvement.

Panelists discuss how proactive adverse event prevention and patient support improve tolerability and continuity of targeted treatment in EGFR-mutant non–small cell lung cancer (NSCLC).

Panelists discuss how dose optimization and personalized adjustment strategies sustain efficacy and enhance long-term outcomes in EGFR-mutant NSCLC.

Panelists discuss how addressing current knowledge gaps and improving real-world integration of emerging therapies will advance care for patients with EGFR-mutant non–small cell lung cancer (NSCLC).